{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:04:37Z","timestamp":1790183077916,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1053\/j.seminoncol.2008.01.008","type":"journal-article","created":{"date-parts":[[2008,6,5]],"date-time":"2008-06-05T12:08:19Z","timestamp":1212667699000},"page":"S34-S43","source":"Crossref","is-referenced-by-count":17,"special_numbering":"S3","title":["Clinical Activity of Vinflunine in Transitional Cell Carcinoma of the Urothelium and Other Solid Tumors"],"prefix":"10.1053","volume":"35","author":[{"given":"Joaquim","family":"Bellmunt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois-Michel","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2008.01.008_bib1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/1568011053352569","article-title":"Targeting microtubules for cancer chemotherapy","volume":"5","author":"Zhou","year":"2005","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib3","doi-asserted-by":"crossref","first-page":"8576","DOI":"10.1021\/ja971864w","article-title":"Vinca alkaloids in superacidic media: a method for creating a new family of antitumor derivatives","volume":"119","author":"Fahy","year":"1997","journal-title":"J Am Chem Soc"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib4","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2174\/1381612013397483","article-title":"Modifications in the \u201cupper\u201d velbenamine part of the Vinca alkaloids have major implications for tubulin interacting activities","volume":"7","author":"Fahy","year":"2001","journal-title":"Curr Pharm Des"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s002800050764","article-title":"Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid","volume":"41","author":"Kruczynski","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib6","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0006-2952(97)00505-4","article-title":"Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid","volume":"55","author":"Kruczynski","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bpc.2006.05.023","article-title":"The thermodynamics of vinca alkaloid-induced tubulin spirals formation","volume":"126","author":"Lobert","year":"2007","journal-title":"Biophys Chem"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s002800051021","article-title":"In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs","volume":"45","author":"Barret","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib9","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/annonc\/mdg174","article-title":"Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours","volume":"14","author":"Bennouna","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib10","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1517\/13543784.14.10.1259","article-title":"Vinflunine: A novel antitubulin agent in solid malignancies","volume":"14","author":"Bennouna","year":"2005","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10637-005-3902-0","article-title":"Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks","volume":"24","author":"Johnson","year":"2006","journal-title":"Invest New Drugs"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1078-1439(02)00184-9","article-title":"Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder","volume":"7","author":"Bonfil","year":"2002","journal-title":"Urol Oncol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib13","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/sj.bjc.6603118","article-title":"A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen","volume":"94","author":"Culine","year":"2006","journal-title":"Br J Cancer"},{"issue":"18S","key":"10.1053\/j.seminoncol.2008.01.008_bib14","first-page":"653s","article-title":"Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urothelium (TCCU)","volume":"25","author":"Vaughn","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1359-6349(07)71165-5","article-title":"Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urothelium (TCCU)","volume":"5","author":"Petrylak","year":"2007","journal-title":"Eur J Cancer Suppl"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib16","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncr.22031","article-title":"Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder","volume":"107","author":"Dash","year":"2006","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib17","first-page":"62","article-title":"Current management of bladder cancer","volume":"6","author":"Galsky","year":"2006","journal-title":"US Oncological Disease"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib18","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1634\/theoncologist.9-6-617","article-title":"Facts and controversies in systemic treatment of metastatic breast cancer","volume":"9","author":"Bernard-Marty","year":"2004","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib19","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/sj.bjc.6603347","article-title":"Vinflunine: A new active drug for second-line treatment of advanced breast cancer","volume":"95","author":"Campone","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/jco.2004.22.14_suppl.542","article-title":"Phase II study of i.v. vinflunine as second line in patients with metastatic breast cancer after anthracycline-taxane failure","volume":"22","author":"Fumoleau","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib21","series-title":"A dose-finding and pharmacokinetic study of I.V. vinflunine (VFL) in combination with capecitabine (CAPE) as second line treatment of metastatic breast cancer (MBC)","author":"Campone","year":"2006"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib22","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ejca.2003.11.007","article-title":"Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer","volume":"40","author":"Fumoleau","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib23","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"Vogel","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib24","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/jco.2007.25.18_suppl.1058","article-title":"Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer","volume":"25","author":"Paridaens","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18S","key":"10.1053\/j.seminoncol.2008.01.008_bib25","first-page":"42s","article-title":"Preliminary results of a multicenter phase II trial of vinflunine (with trastuzumab in HER2+ pts) as first-line treatment in metastatic breast cancer cancer","volume":"28","author":"Peacock","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.lungcan.2006.01.006","article-title":"Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial","volume":"52","author":"Brodowicz","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib27","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1200\/JCO.2001.19.13.3210","article-title":"Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: A Southwest Oncology Group trial","volume":"19","author":"Kelly","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib28","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1200\/JCO.2000.18.1.122","article-title":"Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer","volume":"18","author":"Sandler","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11864-006-0030-9","article-title":"Second- and third-line treatments in non-small cell lung cancer","volume":"7","author":"Kumar","year":"2006","journal-title":"Curr Treat Options Oncol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib30","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/00002820-200603000-00004","article-title":"Quality of life in patients with advanced non-small cell lung cancer","volume":"29","author":"Bozcuk","year":"2006","journal-title":"Cancer Nurs"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib31","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/sj.bjc.6603106","article-title":"Vinflunine \u2013 an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study","volume":"94","author":"Bennouna","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib32","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1200\/jco.2007.25.18_suppl.7511","article-title":"Phase III study of vinflunine versus docetaxel in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a platinum-containing regimen","volume":"25","author":"Krzakowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib33","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/sj.bjc.6603106","article-title":"Vinflunine \u2013 an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study","volume":"94","author":"Bennouna","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib34","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1200\/jco.2004.22.14_suppl.7110","article-title":"Results of a phase I\/II and pharmacokinetic study of vinflunine (VFL) in combination with cisplatin (CDDP) for primary treatment of advanced non-small cell lung cancer (NSCLC)","volume":"22","author":"Ramlau","year":"2004","journal-title":"J Clin Oncol"},{"issue":"16S","key":"10.1053\/j.seminoncol.2008.01.008_bib35","first-page":"688s","article-title":"Phase I and pharmacokinetic study of Vinflunine (VFL) in combination with carboplatin (CBDCA) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts): Final results","volume":"23","author":"Tourani","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib36","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.7271","article-title":"Phase I and pharmacokinetic study of Vinflunine (VFL) in combination with carboplatin (CBDCA) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts): Final results","volume":"23","author":"Tourani","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/CCO.0b013e328011bec3","article-title":"Small cell lung cancer and targeted therapies","volume":"19","author":"Blackhall","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib38","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1556-0864(15)31579-3","article-title":"A review of first-line treatment for small-cell lung cancer","volume":"1","author":"Murray","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib39","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s11912-006-0030-8","article-title":"Second-line treatment of small-cell lung cancer","volume":"8","author":"MacCallum","year":"2006","journal-title":"Curr Oncol Rep"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib40","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.18091","article-title":"Phase II trial of vinflunine in patients with relapsed small cell lung cancer","volume":"25","author":"Peyton","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib41","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1200\/JCO.2003.09.130","article-title":"Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597","volume":"21","author":"Masters","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib42","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/bjc.1998.54","article-title":"A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer","volume":"77","author":"Smit","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib43","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1200\/JCO.2006.08.3998","article-title":"Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer","volume":"25","author":"Eckardt","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib44","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/annonc\/mdi094","article-title":"Chemotherapy options and new advances in malignant pleural mesothelioma","volume":"16","author":"Steele","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib45","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/1097-0142(19831201)52:11<1981::AID-CNCR2820521102>3.0.CO;2-P","article-title":"Malignant mesothelioma","volume":"52","author":"Lerner","year":"1983","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib46","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00175403","article-title":"A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group Study","volume":"6","author":"Zidar","year":"1988","journal-title":"Invest New Drugs"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib47","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00685720","article-title":"Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B","volume":"27","author":"Vogelzang","year":"1990","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib48","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1200\/JCO.2000.18.23.3912","article-title":"Phase II study of vinorelbine in patients with malignant pleural mesothelioma","volume":"18","author":"Steele","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib49","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1200\/JCO.2003.06.122","article-title":"Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma","volume":"21","author":"Scagliotti","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib50","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2008.01.008_bib51","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1200\/JCO.2007.12.5641","article-title":"Phase II study of vinflunine in malignant pleural mesothelioma","volume":"25","author":"Talbot","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18S","key":"10.1053\/j.seminoncol.2008.01.008_bib52","first-page":"102s","article-title":"Phase I and pharmacokinetic (PK) dose-adjusted study of IV vinflunine (VFL) in cancer patients with liver dysfunction (LD): Pharmacokinetic results","volume":"15","author":"Paule","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775408000213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775408000213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T05:21:21Z","timestamp":1588742481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775408000213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":52,"alternative-id":["S0093775408000213"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2008.01.008","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}